<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
  xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.tuobenessere.it/aisla-da-papa-leone-oltre-200-persone-con-sla-familiari-e-volontari/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T18:15:00+02:00</news:publication_date>
      <news:title>Aisla: &quot;Da Papa Leone oltre 200 persone con Sla, familiari e volontari&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/valentini-investimento-in-kedrion-per-competitivita-internazionale/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T17:44:00+02:00</news:publication_date>
      <news:title>Valentini: &quot;Investimento in Kedrion per competitività internazionale&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/marcucci-kedrion-espansione-in-partnership-pubblico-privato-con-mimit/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T17:42:00+02:00</news:publication_date>
      <news:title>Marcucci (Kedrion): &quot;Espansione in partnership pubblico-privato con Mimit&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/di-francesco-kedrion-triplicare-produzione-e-competere-a-livello-globale/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T17:40:00+02:00</news:publication_date>
      <news:title>Di Francesco (Kedrion): &quot;Triplicare produzione e competere a livello globale&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/kedrion-150-milioni-per-triplicare-produzione-plasmaderivati-per-malattie-rare/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T17:39:00+02:00</news:publication_date>
      <news:title>Kedrion: 150 milioni per triplicare produzione plasmaderivati per malattie rare</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/apmarr-rinnova-il-direttivo-antonella-celano-confermata-presidente/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T16:47:00+02:00</news:publication_date>
      <news:title>Apmarr rinnova il direttivo, Antonella Celano confermata presidente</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/tumore-al-polmone-rimborsata-in-italia-terapia-chemio-free-per-mutazioni-egfr/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T16:26:54+02:00</news:publication_date>
      <news:title>Tumore al polmone, rimborsata in Italia terapia chemio-free per mutazioni Egfr</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/hantavirus-cosa-sappiamo/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T15:38:14+02:00</news:publication_date>
      <news:title>Hantavirus, cosa sappiamo</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/cristalfarma-prosegue-gli-investimenti-sui-suoi-integratori-avanzati-e-rafforza-quelli-sul-vertical/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T14:23:17+02:00</news:publication_date>
      <news:title>Cristalfarma prosegue gli investimenti sui suoi integratori avanzati e rafforza quelli sul vertical</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/lega-filo-doro-alla-conferenza-nazionale-quasi-100-persone-con-sordocecita/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T13:29:00+02:00</news:publication_date>
      <news:title>Lega Filo d&#039;Oro, alla Conferenza nazionale quasi 100 persone con sordocecità</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/cancro-al-seno-metastatico-pfizer-lancia-campagna-sulla-qualita-di-vita-delle-donne/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T13:06:00+02:00</news:publication_date>
      <news:title>Cancro al seno metastatico, Pfizer lancia campagna sulla qualità di vita delle donne</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/tumori-72mila-morti-evitabili-lanno-accordo-aiom-e-tennisfriends-su-prevenzione/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-05-11T11:59:00+02:00</news:publication_date>
      <news:title>Tumori, &#039;72mila morti evitabili l&#039;anno&#039;: accordo Aiom e Tennis&amp;Friends su prevenzione</news:title>
    </news:news>
  </url>
</urlset>
<!-- Generated: 2026-05-11 20:36:23 | Posts: 12 -->
